# SLC6A2

## Overview
The SLC6A2 gene encodes the norepinephrine transporter (NET), a transmembrane protein that plays a critical role in the reuptake of norepinephrine from the synaptic cleft into presynaptic neurons. This transporter is integral to the regulation of neurotransmitter levels, thereby influencing various physiological processes such as mood, attention, and stress response (Pramod2013SLC6; Dong2009Sequence). NET is characterized by its 12 transmembrane alpha-helical domains and a 5+5 inverted repeat fold, which are typical features of secondary active transporters (Kristensen2011SLC6). The protein's function is modulated by interactions with other proteins and post-translational modifications, which can affect its expression and activity (Wang2010Emerging; Kristensen2011SLC6). Variations in the SLC6A2 gene have been linked to several neuropsychiatric and cardiovascular disorders, underscoring its clinical significance (Kim2021Association; Xia2024Relationship).

## Structure
The SLC6A2 gene encodes the norepinephrine transporter (NET), a protein integral to neurotransmitter reuptake. The primary structure of NET consists of 617 amino acids, organized into 12 transmembrane (TM) alpha-helical domains, which are highly hydrophobic and typical of transporters facilitating neurotransmitter movement across cell membranes (Belfer2004Haplotype; Benarroch2013Monoamine). The secondary structure includes these TM helices, forming a cylindrical shape with an extracellular vestibule and an inner ring containing the substrate binding pocket (Benarroch2013Monoamine).

The tertiary structure of NET is characterized by a 5+5 inverted repeat fold, a structural motif common in secondary active transporters, consisting of two similar five-helix bundles arranged in a pseudosymmetric inverted-repeat architecture (Kristensen2011SLC6). This structure includes a central substrate binding site (S1) and Na+ binding sites, crucial for its function (Kristensen2011SLC6). The protein also features a large glycosylated loop between TMIII and TMIV and a pair of cysteine residues in extracellular loop 2 that form a disulfide bridge (Benarroch2013Monoamine).

Post-translational modifications such as glycosylation and phosphorylation influence the function and expression of NET (Wang2010Emerging). The SLC6A2 gene also has five alternative splice transcripts, which may result in isoforms with differing functional properties (Belfer2004Haplotype).

## Function
The SLC6A2 gene encodes the norepinephrine transporter (NET), a crucial protein for the reuptake of norepinephrine from the synaptic cleft back into presynaptic neurons. This process is essential for terminating norepinephrine signal transmission and maintaining neurotransmitter homeostasis in the nervous system (Pramod2013SLC6; Belfer2004Haplotype). NET is primarily active in the central and peripheral nervous systems, particularly in noradrenergic neurons, where it regulates various physiological processes, including mood, attention, learning, and stress responses (Dong2009Sequence; Bayles2013Methylation).

In healthy human cells, the proper functioning of NET ensures efficient norepinephrine reuptake, which is vital for normal neurotransmission and the regulation of emotional and physiological responses (Bayles2013Methylation). The transporter also plays a role in the uptake of dopamine, contributing to the regulation of monoamine neurotransmitter levels (Belfer2004Haplotype). The activity of NET is influenced by various factors, including genetic variations and methylation patterns, which can affect its expression and function, potentially impacting physiological and psychological states (Pramod2013SLC6; Bayles2013Methylation).

## Clinical Significance
Mutations and alterations in the SLC6A2 gene, which encodes the norepinephrine transporter (NET), have been associated with several psychiatric and cardiovascular conditions. Variants in this gene can influence norepinephrine reuptake, impacting mood regulation and stress responses. For instance, the rs28386840 SNP in the SLC6A2 gene has been linked to a reduced risk of developing bipolar I disorder, suggesting a protective role of the T allele in this condition (Kim2021Association). 

The SLC6A2 gene is also implicated in the pathogenesis of post-traumatic stress disorder (PTSD), with polymorphisms affecting brain volume in specific regions, such as the left superior parietal gyrus and bilateral middle cingulate gyrus, in individuals who have experienced significant trauma (Xia2024Relationship). Additionally, epigenetic modifications of the SLC6A2 gene, such as DNA methylation, have been associated with essential hypertension and panic disorder, indicating that changes in gene expression can contribute to these conditions (Pramod2013SLC6).

Despite these associations, some studies have not found significant links between SLC6A2 polymorphisms and major psychiatric disorders, highlighting the complexity of genetic contributions to these conditions (Stöber1996Systematic).

## Interactions
The SLC6A2 gene encodes the norepinephrine transporter (NET), which is involved in the reuptake of norepinephrine from the synaptic cleft. NET interacts with several proteins that modulate its function and trafficking. One significant interaction is with syntaxin 1A, a SNARE protein that binds to the N-terminus of NET. This interaction affects the transporter's cell surface availability and catalytic activity, influencing neurotransmitter regulation and synaptic transmission (Kristensen2011SLC6).

NET also interacts with the protein PICK1, which is involved in enhancing the surface targeting and clustering of the transporter. This interaction is crucial for the regulation of NET's function and its response to various drugs (Kristensen2011SLC6).

Additionally, the norepinephrine transporter is involved in interactions with other proteins such as 14-3-3, PP2A, and α-Synuclein, which occur at different sites on the transporter, including the N-terminus and C-terminus. These interactions are part of the regulatory mechanisms that control the transporter's activity and its role in neurotransmission (Kristensen2011SLC6).

These protein-protein interactions are essential for the proper functioning of NET and have implications for its role in various neuropsychiatric disorders.


## References


[1. (Dong2009Sequence) C Dong, M-L Wong, and J Licinio. Sequence variations of abcb1, slc6a2, slc6a3, slc6a4, creb1, crhr1 and ntrk2: association with major depression and antidepressant response in mexican-americans. Molecular Psychiatry, 14(12):1105–1118, October 2009. URL: http://dx.doi.org/10.1038/mp.2009.92, doi:10.1038/mp.2009.92. This article has 142 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/mp.2009.92)

[2. (Kristensen2011SLC6) Anders S. Kristensen, Jacob Andersen, Trine N. Jørgensen, Lena Sørensen, Jacob Eriksen, Claus J. Loland, Kristian Strømgaard, and Ulrik Gether. Slc6 neurotransmitter transporters: structure, function, and regulation. Pharmacological Reviews, 63(3):585–640, July 2011. URL: http://dx.doi.org/10.1124/pr.108.000869, doi:10.1124/pr.108.000869. This article has 679 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.108.000869)

[3. (Xia2024Relationship) Zhuoman Xia, Zhihong Cao, Wesley Surento, Li Zhang, Lianli Qiu, Qiang Xu, Longjiang Zhang, Lingjiang Li, Yang Cao, Yifeng Luo, Guangming Lu, and Rongfeng Qi. Relationship between slc6a2 gene polymorphisms and brain volume in han chinese adults who lost their sole child. BMC Psychiatry, January 2024. URL: http://dx.doi.org/10.1186/s12888-023-05467-4, doi:10.1186/s12888-023-05467-4. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s12888-023-05467-4)

[4. (Wang2010Emerging) Ching-I Anderson Wang and Richard J. Lewis. Emerging structure–function relationships defining monoamine nss transporter substrate and ligand affinity. Biochemical Pharmacology, 79(8):1083–1091, April 2010. URL: http://dx.doi.org/10.1016/j.bcp.2009.11.019, doi:10.1016/j.bcp.2009.11.019. This article has 30 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2009.11.019)

[5. (Kim2021Association) Sun-Young Kim, Han-Na Kim, Sang Won Jeon, Weon-Jeong Lim, Soo In Kim, Youn Jung Lee, Se Young Kim, and Yong-Ku Kim. Association between genetic variants of the norepinephrine transporter gene (slc6a2) and bipolar i disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 107:110227, April 2021. URL: http://dx.doi.org/10.1016/j.pnpbp.2020.110227, doi:10.1016/j.pnpbp.2020.110227. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pnpbp.2020.110227)

[6. (Benarroch2013Monoamine) Eduardo E. Benarroch. Monoamine transporters: structure, regulation, and clinical implications. Neurology, 81(8):761–768, August 2013. URL: http://dx.doi.org/10.1212/WNL.0b013e3182a1ab4a, doi:10.1212/wnl.0b013e3182a1ab4a. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1212/WNL.0b013e3182a1ab4a)

[7. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[8. (Belfer2004Haplotype) Inna Belfer, Gabriel Phillips, Julie Taubman, Heather Hipp, Robert H. Lipsky, Mary-Anne Enoch, Mitchell B. Max, and David Goldman. Haplotype architecture of the norepinephrine transporter gene slc6a2 in four populations. Journal of Human Genetics, 49(5):232–245, April 2004. URL: http://dx.doi.org/10.1007/s10038-004-0140-9, doi:10.1007/s10038-004-0140-9. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10038-004-0140-9)

[9. (Bayles2013Methylation) Richard Bayles, Emma K. Baker, Jeremy B. M. Jowett, David Barton, Murray Esler, Assam El-Osta, and Gavin Lambert. Methylation of the slc6a2 gene promoter in major depression and panic disorder. PLoS ONE, 8(12):e83223, December 2013. URL: http://dx.doi.org/10.1371/journal.pone.0083223, doi:10.1371/journal.pone.0083223. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0083223)

[10. (Stöber1996Systematic) Gerald Stöber, Markus M. Nöthen, Peter Pörzgen, Michael Brüss, Heinz Bönisch, Michael Knapp, Helmut Beckmann, and Peter Propping. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. American Journal of Medical Genetics, 67(6):523–532, November 1996. URL: http://dx.doi.org/10.1002/(SICI)1096-8628(19961122)67:6<523::AID-AJMG3>3.0.CO;2-I, doi:10.1002/(sici)1096-8628(19961122)67:6<523::aid-ajmg3>3.0.co;2-i. This article has 152 citations.](https://doi.org/10.1002/(SICI)1096-8628(19961122)67:6)